Accelerate timelines and navigate complexity with a proven pancreatic cancer CRO
When someone is diagnosed with pancreatic cancer, the diagnosis is often late, treatment is challenging, and long-term survival is low. It’s a difficult diagnosis for patients and their families to face. But with new treatments like yours, patients get more options and opportunities.
At Parexel, we’re a global pancreatic cancer CRO that offers integrated services across every phase of clinical development, bringing innovation and expertise to your project so you can recruit the patients you need, navigate scientific and regulatory complexities, and change lives everywhere. We can help you with:
- Novel targeted therapies
- Immunotherapies and combination approaches
- Neoadjuvant and adjuvant treatment strategies
- Biomarker-driven precision medicine approaches
- Studies for both localized and metastatic disease
- Supportive care interventions
Experience in the past 5 years in pancreatic cancer
clinical projects
+
patients
+
sites
Advantages
Proven oncology expertise
Our dedicated oncology team has extensive expertise in gastrointestinal cancers. That includes over 100 staff with pancreatic cancer therapy experience specifically. We understand the evolving standards of care for pancreatic cancer and how to apply the right innovations and approaches to your trial.
Advanced patient recruitment & retention
As your pancreatic cancer CRO, we offer patient recruitment and retention strategies to help you navigate this cancer’s unique challenges. Aggressive disease progression, late diagnosis, resistance to therapies, and disease heterogeneity all make it harder to find the right patients and keep them engaged. But through patient education, surveys, burden analyses, and other tactics — including guidance from Chief Patient Officer Stacy Hurt, who’s a cancer survivor herself — we can help achieve your goals.
Innovative study designs
We design your trials with the latest innovations and capabilities, tailoring them to address the unique challenges of pancreatic cancer. We use adaptive trial designs to address disease heterogeneity, biomarker-driven strategies to hone in on patient populations, real-world evidence to support traditional clinical endpoints, and more.
Global regulatory strategy and support
Our regulatory strategy team is 1,000+ strong, with proven experience navigating pancreatic cancer studies around the world. We’re staffed with around 50 former regulators from around the world, covering 110 countries and submitting 1,350+ product reviews and annual reports each year. We’re ready to guide your pancreatic cancer therapy every step of the way to approval and beyond.
Biomarker expertise
Our experience as an oncology CRO includes experience working with all types of biomarkers, including genomics, transcriptomics, proteomics, and metabolomics. We also have deep expertise in biomarker strategy development for patient stratification and targeted therapy approaches.